Experienced Drug Developers and Groundbreaking Scientists

At TriGemX, we focus on big health challenges that matter to patients and families. We are developing an effective, easy to use, well-tolerated agent addressing the needs of migraine patients.

Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, including a seasoned team with a proven track record of success.

Board of Directors

Jeff Goater

The Column Group

Peter Hecht, Ph.D.

Tisento Therapeutics

William Rieflin

Independent

Amy Schulman

Polaris Partners

Josh Wolfe

Lux Capital

Strategic Advisor

Terry McGuire